Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Open access

Published version of a preprint

Abstract

Immune checkpoint therapies targeting CTLA-4 and PD-1 have proven effective in cancer treatment. However, the identification of biomarkers for predicting clinical outcomes and mechanisms to overcome resistance remain as critical needs. Angiogenesis is increasingly appreciated as an immune modulator with potential for combinatorial use with checkpoint blockade. Angiopoietin-2 (ANGPT2) is an immune target in patients and is involved in resistance to anti-VEGF treatment with the monoclonal antibody bevacizumab. We investigated the predictive and prognostic value of circulating ANGPT2 in metastatic melanoma patients receiving immune checkpoint therapy. High pretreatment serum ANGPT2 was associated with reduced overall survival in CTLA-4 and PD-1 blockade–treated patients. These treatments also increased serum ANGPT2 in many patients early after treatment initiation, whereas ipilimumab plus bevacizumab treatment decreased serum concentrations. ANGPT2 increases were associated with reduced response and/or overall survival. Ipilimumab increased, and ipilimumab plus bevacizumab decreased, tumor vascular ANGPT2 expression in a subset of patients, which was associated with increased and decreased tumor infiltration by CD68+ and CD163+ macrophages, respectively. In vitro, bevacizumab blocked VEGF-induced ANGPT2 expression in tumor-associated endothelial cells, whereas ANGPT2 increased PD-L1 expression on M2-polarized macrophages. Treatments elicited long-lasting and functional antibody responses to ANGPT2 in a subset of patients receiving clinical benefit. Our findings suggest that serum ANGPT2 may be considered as a predictive and prognostic biomarker for immune checkpoint therapy and may contribute to treatment resistance via increasing proangiogenic and immunosuppressive activities in the tumor microenvironment. Targeting ANGPT2 provides a rational combinatorial approach to improve the efficacy of immune therapy. Cancer Immunol Res; 5(1); 17–28. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0206

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 60 references

Cited by

See all 180

Metadata

Authors
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., Zhou, J., Gjini, E., Lako, A., Lipschitz, M., Pak, C. J., Abdelrahman, S., Rodig, S., & Hodi, F. S.
Affiliations
  • Harvard University (US)
  • 2Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Brigham and Women's Hospital (US)
  • Massachusetts General Hospital (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Hodi, F. Stephen
Venue
Cancer Immunology Research
Published
2017-01-01
Volume
5
Issue
1
Pages
17-28
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2565119421
Cited by
164
References
60
Citations by year
2026: 9 · 2025: 16 · 2024: 7 · 2023: 19 · 2022: 14 · 2021: 23 · 2020: 27 · 2019: 20 · 2018: 16 · 2017: 12
FWCI
8.62
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (R21CA143832)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
angiopoietin-2, immune checkpoint therapy, CTLA-4 blockade, anti-PD-1 therapy, metastatic melanoma, predictive biomarkers, prognostic factors, bevacizumab, ipilimumab, anti-VEGF therapy resistance, tumor microenvironment, tumor-associated macrophages, M2 macrophages, PD-L1, tumor angiogenesis, treatment resistance, circulating biomarkers
MeSH terms
Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Humans, Macrophages, Neoplasms, Neovascularization, Pathologic, Biomarkers, Tumor, Biomarkers, Survival Analysis, Treatment Outcome, Vascular Endothelial Growth Factor A, Angiopoietin-2, Immunomodulation, Molecular Targeted Therapy, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. https://app.cochat.ai/papers/10.1158/2326-6066.cir-16-0206
The paper
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., Zhou, J., Gjini, E., Lako, A., Lipschitz, M., Pak, C. J., Abdelrahman, S., Rodig, S., & Hodi, F. S. (2017). Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-16-0206

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.